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Abstract Patients with complete IFN-γR deficiency are unable to respond to IFN-γ and have
impaired Th1-immunity and recurrent, severe infections with weakly virulent Mycobacteria.
Since IFN-α and IFN-γ share signalling pathways, treatment with IFN-α has been proposed in
complete IFN-γR deficiency. We stimulated cells from healthy controls and from a patient
lacking IFN-γR1 with IFN-α and IFN-γ, to establish whether IFN-α would substitute for IFN-γ
effects. IFN-α induced STAT1 phosphorylation in monocytes of the IFN-γR1­/­ patient, but did not
prime for LPS-induced IL-12p70, IL-12p40, IL-23 or TNF production. In control cells, IFN-α
inhibited the priming effect of IFN-γ on LPS-induced pro-inflammatory cytokine release. Finally,
IFN-γ but not IFN-α induced killing of M. smegmatis in cultured macrophages. In conclusion, no
evidence was found to support the use of IFN-α in IFN-γR-deficient patients as intervention
against mycobacterial infection; on the contrary, treatment of individuals with IFN-α may even
adversely affect host defence against Mycobacteria.
© 2010 Elsevier Inc. Open access under the Elsevier OA license. 526 6758.
mc.nl (E. van de Vosse).
cess under the Elsevier OA license. 1. Introduction
Patients with unusual, persistent and severe infections
caused by otherwise poorly pathogenic Mycobacteria have
a condition known as Mendelian Susceptibility to Mycobac-
terial Disease (MSMD). MSMD is a heterogeneous disorder that
can be caused by mutations in the IL12B, IL12RB1, IFNGR1,
IFNGR2 and STAT1 genes that are involved in the IL-12/-23/
IFN-γ cytokine signalling cascade [1]. Due to these defects,no effective immune response is generated in response to
mycobacterial infection. Patients with IL-12p40 or IL-12Rβ1
deficiency are unable to produce or respond to IL-12 and
IL-23. Since IL-12 and IL-23 signalling is imperative for IFN-γ
production, these patients do not produce sufficient IFN-γ to
control infections. These patients benefit from treatment
with recombinant IFN-γ in addition to antibiotics [2].
Patients with partial IFN-γR deficiency also benefit from
treatment with high dose recombinant IFN-γ [3]. A more
severe clinical course is seen in complete IFN-γR1 and IFN-
γR2 deficient patients whereby these individuals often
succumb to mycobacterial infections very early in life [1].
Patients with complete IFN-γR1 or IFN-γR2 deficiencies are
unable to respond to IFN-γ and thus will not benefit from
treatment with recombinant IFN-γ. The only currently
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283Effect of IFN-α on IFN-γR1 deficient cellsavailable curative treatment of complete IFN-γR deficiency
is hematopoietic stem cell transplantation; however, the
overall success rate of stem cell transplantation in this
setting is low.
Treatment with IFN-α as additional therapy has been
described in two patients, with complete IFN-γR1 and
complete IFN-γR2 deficiency, respectively, suffering from
disseminated infection with Mycobacterium avium complex
[4,5]. The rationale behind this therapy being that IFN-α
and IFN-γ activate common signalling pathways and the
induced genes and biological effects partly overlap. Through
the activation of overlapping effects of IFN-α and IFN-γ,
treatment with exogenous IFN-α is thought to (partly)
compensate for the absence of IFN-γ signalling in patients
deficient in IFN-γR1 or IFN-γR2. The IFN-α receptor is
composed of IFN-αR1 and IFN-αR2 subunits, associated with
Janus kinases (JAKs) TYK2 and JAK1. In response to IFN-α,
these JAKs are activated and subsequently phosphorylate
signal transducer and activator of transcription (STAT) 1 and
STAT2 [6]. STAT1 and STAT2 form heterodimers, which
associate with interferon regulatory factor-9 (IRF-9) to form
a STAT1/STAT2/IRF-9 complex (also known as IFN-stimulated
gene factor 3 (ISGF3)) [7]. This complex migrates to the
nucleus and regulates primary response genes by binding
specific DNA response elements. IFN-γ signals via the IFN-
γR1 and IFN-γR2. Upon binding of IFN-γ, receptor-associated
JAK1 and JAK2 are phosphorylated, which in mature
monocytes and macrophages leads to phosphorylation of
STAT1 [8]. STAT1 dimerizes and translocates to the nucleus
to regulate primary response gene transcription [8]. STAT1
can, in theory, also form homodimers in response to IFN-α
[9]. IFN-α signalling is not affected by deficiencies of the IFN-
γR1 or the IFN-γR2.
The potential effect of IFN-α treatment in patients with
complete IFN-γR deficiency has not been investigated at the
cellular level. We therefore determined whether IFN-α can
(partly) compensate for absence of IFN-γ signalling in cells
obtained from an IFN-γR1 deficient patient.STAT1p
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Figure 1 IFN-α induces STAT1 phosphorylation in monocytes
from an IFNγR1 deficient patient. Healthy control (A) or patient
(B) derived PBMC were stimulated with 1000 U/ml IFN-α,
2.5 ng/ml IFN-γ, 1000 U/ml IFN-α plus 2.5 ng/ml IFN-γ,
or left unstimulated for 15 min. Cells were labeled with
anti-human pSTAT1-Alexa 647 and CD64-FITC antibodies and
analyzed by FACS. Histograms shown are gated on CD64 positive
monocytes. In monocytes from a healthy control, IFN-α, IFN-γ
and IFN-α plus IFN-γ induced STAT1 phosphorylation. In
monocytes from the patient IFN-α and IFN-α plus IFN-γ induced
STAT1 phosphorylation, whereas stimulation with IFN-γ alone
did not.2. Materials and methods
2.1. Cell culture conditions and infections
Human CD14+ cells and PBMCs were isolated from healthy
donor buffy coats (Sanquin) or from blood from healthy
consenting volunteers, or an IFN-γR1 deficient patient (P2 in
[10]), by Ficoll-Amidotrizoate density gradient centrifuga-
tion and subsequent selection with anti-CD14 MACS beads
(Miltenyi Biotech). The purity of monocytes selected with
anti-CD14 MACS beads is typically 95–98% in our hands.
CD14+ cells were cultured in RPMI-1630 medium, supple-
mented with 20 mM GlutaMAX (Gibco/ Invitrogen), 10% FCS,
100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco/
Invitrogen).
For assessment of in vitro mycobactericidal activity as
described [12], CD14+ cells were cultured for 6 days in the
presence of 5 ng/ml GM-CSF (Biosource) to generate pro-
inflammatory macrophages (Mφ1) as previously described
[11]. These cells were seeded at 3 × 105 in 24-well plates, left
to adhere then treated with IFN-α (IFN-α2b (Intron®A)/IFN-
α2a (Roferon®A)) and/or IFN-γ (Immukine®, Boehringer) orH-89 (Sigma Aldrich) overnight prior to infecting with log
phase growth M. smegmatis::GFP at an MOI of 1. Extracel-
lular mycobacteria were eliminated by low dose gentamycin
treatment (5 μg/ml) for the duration of the experiment. All
cells were subsequently collected, lysed, plated out on 7H9
agar plates and levels of fluorescence were assayed in a
Mithras LB940 plate reader after 24 h.
All research involving patient material was approved by
the Leiden University Medical Center-Medical Ethical Com-
mittee. This research was conducted in accordance with the
Declaration of Helsinki.
Figure 2 IFN-α does not upregulate CD64 or CD54 expression in monocytes. (A and C) PBMC obtained from a healthy control were
incubated with 2.5 ng/ml IFN-γ, 1000 U/ml IFN-α or 2.5 ng/ml IFN-γ plus 1000 U/ml IFN-α for 24 h. CD14+ monocytes were gated and
analyzed for (A) CD64 expression and (C) CD54 expression. IFN-γ upregulated CD64 and CD54 expression, whereas IFN-α had no effect
on CD64 cell surface expression, while it downregulated CD54 expression; IFN-α inhibited the IFN-γ induced CD64 and CD54
upregulation. (B and D) IFN-γR1 deficient PBMC were stimulated with IFN-γ or IFN-α, or both IFN-γ and IFN-α for 24 h and CD64 and
CD54 expression on CD14+ monocytes was assessed by FACS. (B) Neither IFN-γ, nor IFN-α or IFN-γ plus IFN-α upregulated CD64
expression substantially. (D) While IFN-γ did not have an effect on CD54 expression, both IFN-α and IFN-γ plus IFN-α downregulated
CD54 expression. (E) The median fluorescence of CD64 and CD54 expression analyses from (A) to (D).
Figure 3 IFN-α does not prime monocytes for enhanced pro-inflammatory cytokine production in response to LPS. Control (A–E)
and patient (F–K) derived monocytes were stimulated with 100 ng/ml LPS plus or minus indicated concentrations (in units/ml) IFN-α
and/or 2.5 ng/ml IFN-γ for 24 h. IL-12p40 (A and F), IL-12p70 (B and G), IL-23 (C and H), TNF (D and I) and IL-1β (E and K)
concentrations were determined by ELISA. Depicted are average protein concentrations of 4 control donors (A–E) and average protein
concentrations of triplicates of an experiment with patient-derived cells (F–K). The bars indicate the standard deviation (SD). nd=not
detectable. For statistical analysis, one-way ANOVAs and Bonferroni tests for selected columns were performed. n.s. = not significant.
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To assess STAT1 phosphorylation, PBMC were stimulated with
recombinant human 2.5 ng/ml IFN-γ (Biosource) or 1000 U/
ml IFN-α for 15 min, or left unstimulated. Cells were fixed
with 4% paraformaldehyde and permeabilised with 90%
methanol, then labeled with anti-phospho-STAT1 (pY701)-
PE antibody (BD Biosciences). To assess CD64 and CD54
regulation in response to IFN-γ/α, PBMC were seeded 5 × 105
per well in hydron coated 24-well plates (Corning Life
Sciences) and stimulated overnight with 2.5 ng/ml IFN-γ
and/or 1000 U/ml IFN-α, or left unstimulated. Cells were
stained with anti-CD64-FITC, anti-CD54-PE and anti-CD14-PE
antibodies and analyzed on a FACS Calibur/CellQuest Pro (BD
Biosciences).
2.3. Cytokine induction and measurement
CD14+-bead-isolated monocytes were seeded in 96-well
plates at 1 × 105 cells per well and cultured for 24 h in the
presence or absence of 100 ng/ml LPS (Sigma), with and
without various concentrations of IFN-α and/or 2.5 ng/ml
IFN-γ. Cell free supernatants were collected and TNF, IL-1β,
IL-10, IL-12p40 (Biosource), IL-12p70 (BD Biosciences) and
IL-23 (eBioscience) concentrations were determined by
ELISA.
3. Results
3.1. IFN-α, but not IFN-γ, induces STAT1
phosphorylation in monocytes from an IFN-γR1
deficient patientSTAT1 phosphorylation can be induced by both IFN-α and IFN-
γ [13]. STAT1 could therefore be an important factor in
inducing potential overlapping effects of these two inter-
ferons. To compare IFN-α and IFN-γ induced STAT1 phos-
phorylation, PBMCs were stimulated with IFN-α, IFN-γ or
both interferons and STAT1 phosphorylation in CD14+
monocytes was assessed by FACS.
In monocytes obtained from healthy donors, STAT1
phosphorylation was observed in response to IFN-α and IFN-
γ as well as to both together (Fig. 1A). Of note, the response
to IFN-α plus IFN-γwas not higher than the response to either
interferon alone (Fig. 1A). In monocytes derived from an IFN-
γR1 deficient patient, STAT1 phosphorylation was induced in
the presence of IFN-α but not in response to IFN-γ (Fig. 1B).
3.2. IFN-α does not substitute IFN-γ-mediated
upregulation of CD64 and CD54 cell surface
expression in monocytes
IFN-γ induces an increase in the cell surface expression of
the high affinity IgG receptor, FcγRI (CD64) in monocytes
and macrophages, enhancing phagocytosis, binding of
immune-complexes, and antibody-dependent cellular cyto-
toxicity [14]. This upregulation is mediated by IFN-γ-
induced STAT1 phosphorylation and subsequent STAT1
binding to the CD64 promoter, thereby increasing transcrip-tion and translation of the gene [9]. Likewise, IFN-γ
enhances the expression of CD54 (ICAM-1) [15]. CD54 is
involved in the adhesion to endothelial cells and transmi-
gration into tissues [16], and functions as a costimulatory
molecule on APC and other cell types, to activate CD4+ T
cells and cytotoxic CD8+ T cells, respectively [17]. To
determine whether the IFN-α-induced STAT1 phosphoryla-
tion also upregulates CD64 and CD54 expression, PBMCs
were stimulated with IFN-α, IFN-γ, or both these interfer-
ons, and analyzed by FACS. In monocytes from healthy
controls, IFN-γ enhanced the expression of CD64 and CD54,
whereas IFN-α did not (Fig. 2A and C), IFN-α rather appears
to downregulate CD54 expression. By contrast, in patient's
monocytes lacking IFN-γR1, neither IFN-α nor IFN-γ affect-
ed CD64 expression (Fig. 2B), IFN-γ also did not affect CD54
expression, while similar to the control IFN-α downregu-
lated CD54 expression (Fig. 2D). Moreover, upon stimulation
of monocytes of healthy controls by both IFN-α plus IFN-γ,
IFN-α reversed IFN-γ-dependent upregulation of CD64 and
CD54 (Fig. 2A and D). In Fig. 2E the median fluorescence
values of Fig. 2A–D are given.3.3. IFN-α does not synergize with LPS to induce
pro-inflammatory cytokines in monocytes
Cytokines such as IL-12, IL-23, TNF and IL-1β play an
important role in controlling mycobacterial infections
[18,19]. During an immune response, IFN-γ produced by
innate immune cells provides a strong positive feedback loop
to enhance secretion of IL-12, IL-23, TNF and IL-1β by
monocytes and macrophages in response to Toll-like recep-
tor (TLR) stimuli such as lipopolysaccharide (LPS) [8,20,21].
To compare effects of IFN-α with the effects of IFN-γ on the
LPS-induced cytokine production, monocytes were stimulat-
ed with LPS in combination with IFN-α or IFN-γ and
supernatants assayed for cytokine secretion.
IFN-γ enhanced the IL-12p40, IL-12p70, IL-23, TNF and
IL-1β production induced by LPS in monocytes from healthy
donors (Fig. 3A–E). By contrast, IFN-α did not prime for
enhanced cytokine production in response to LPS in
monocytes from healthy controls (Fig. 3A–E). In cells
obtained from an IFN-γR1 deficient patient, IFN-α could
not substitute for IFN-γ as no priming effect was observed
(Fig. 3F–K). Moreover, IFN-α decreased LPS-induced
IL-12p40, IL-23 and IL-1β production in cells from the
patient (Fig. 3F, H and K). No significant effect of IFN-α was
observed on LPS-induced TNF production. Of note, patient-
derived monocytes secreted about a four-fold higher
amount of IL-12p40 in the absence of interferons as
compared to control monocytes.
Opposing effects of IFN-α and IFN-γ on LPS-induced
IL-12p40, IL-23 and IL-1β production observed above
prompted us to assess the effects of adding both interferons,
together, to stimulate pro-inflammatory cytokine release
by monocytes from healthy controls. When monocytes were
stimulated with LPS in combination with both interferons,
IFN-α inhibited the priming effect of IFN-γ: IL-12p40,
IL-12p70, IL-23, TNF and IL-1β production were reduced
compared to cells stimulated with LPS and IFN-γ (Fig. 3A–E).
This inhibiting effect of IFN-α occurred in a dose-dependent
fashion.
287Effect of IFN-α on IFN-γR1 deficient cells3.4. Both IFN-γ and IFN-α inhibit LPS-induced IL-10
production in monocytes
Monocytes primed with IFN-γ release less anti-inflammatory
cytokine IL-10 in response to LPS [22], thereby favouring a
pro-inflammatory response. In the IFN-γR1-deficient patient
the inhibiting effect of IFN-γ on IL-10 production is absent,
which may result in relative overproduction of IL-10. We
tested whether IFN-α could substitute for absence of an
IFN-γ effect in IFN-γR1 deficient cells to reduce LPS-induced
IL-10 production. In cells from healthy donors, IFN-γ and
IFN-α each inhibited LPS-induced IL-10 production while the
strongest reduction of IL-10 was observed in cells incubated
with both interferons (Fig. 4A). LPS-induced IL-10 production
by IFN-γR1 deficient monocytes was slightly, but signifi-IF
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Figure 4 IFN-α inhibits LPS-induced IL-10 production in
monocytes. Control (A) and patient (B) derived monocytes
were stimulated with 100 ng/ml LPS plus or minus indicated
concentrations (U/ml) IFN-α and/or 2.5 ng/ml IFN-γ for 24 h.
IL-10 concentration in supernatants was determined by ELISA.
Depicted are average protein concentrations of 4 control
donors (A) and average protein concentrations of triplicates
of an experiment with patient-derived cells (B). The bars
indicate the SD. For statistical analysis, one-way ANOVAs and
Bonferroni tests for selected columns were performed. n.s. = not
significant.cantly, inhibited by IFN-α, but – as expected – not by IFN-γ.
No additive effect of adding IFN-γ to IFN-α was observed
(Fig. 4B).
Similar inhibiting effects of IFN-γ and IFN-α on IL-10
production were observed in five experiments with LPS-
stimulated whole blood of healthy controls; in a whole blood
assay with patient-derived blood, no IFN-γ effect was seen,
while IFN-α inhibited LPS-induced IL-10 production (data not
shown).3.5. IFN-γ but not IFN-α induces killing of M.
smegmatis in human macrophages
To determine whether IFN-α, like IFN-γ, induces killing of
intracellular pathogens in macrophages, we tested both
interferons on the intracellular survival of Mycobacterium
smegmatis. Pro-inflammatory macrophages isolated and
differentiated from healthy donors were pre-stimulated
with IFN-α, IFN-γ or both interferons and subsequently
infected with M. smegmatis-GFP. As a control, infected
macrophages were treated with H-89, a kinase inhibitor
known to inhibit intracellular growth of mycobacteria [12].
The intracellular load of M. smegmatis was assayed by
fluorimetry. As expected, H-89 severely reduced intracellu-
lar growth of M. smegmatis (Fig. 5). IFN-γ treatment dose-
dependently induced mycobactericidal activity in macro-
phages, whereas IFN-α showed no such activity. Additionally,
upon treatment with both interferons IFN-α acted to reverse
mycobactericidal effects of IFN-γ (Fig. 5).0
20000
40000
60000
80000
100000
120000
140000
u
n
tre
at
ed
50
 IF
N-
γ
50
0 
IF
N-
γ
IF
N
-α
50
 IF
N-
γ +
IF
N
-α
50
0 
IF
N-
γ +
IF
N
-α H
-8
9
ba
ct
er
ia
l o
ut
gr
ow
th
 (R
LU
) p<0.005
p<0.001
n.s.
p<0.001
n.s.
p<0.005
p<0.001
p<0.001.
Figure 5 IFN-γ, but not IFN-α, induces bactericidal activity to
M. smegmatis in infectedmacrophages. Culturedpro-inflammatory
macrophages were stimulated with IFN-α (1000 U/ml), IFN-γ (50 or
500 U/ml), IFN-α plus IFN-γ, H-89 (10 μM) or left unstimulated for
16 h prior to infection with M. smegmatis-GFP at a MOI of 1.
Intracellular growth of M. smegmatis-GFP was assessed by
fluorimetry 24 h post-infection. Data shown is average of 13
data points on duplicate experiments. For statistical analysis,
non-parametric Mann–Whitney tests were performed. n.s. = not
significant.
288 D. de Wetering et al.4. DiscussionThe main observation in the present study is that IFN-α lacks
the ability to compensate or substitute for the absence of IFN-
γ-activating effect in monocytes and macrophages of a patient
with complete IFN-γR1 deficiency. The absence of an IFN-α
effect was demonstrated with respect to the LPS-induced
pro-inflammatory cytokine release by these cells, the upregu-
lation of CD64 and CD54 cell surface expression, as well as
engagement of bactericidal processes, all considered markers
of IFN-γ activation signalling. Moreover, in cells from healthy
controlswe observed a negative effect on LPS-induced IL-12p40
and IL-23 production and cell surfacemarker upregulation upon
adding IFN-α to IFN-γ-stimulated cells. Thus, although we
confirm that IFN-α, like IFN-γ, is capable of inducing STAT1
phosphorylation, our findings do not support the use of IFN-α in
patients lacking the ability to respond to IFN-γ.
Ward et al. describe adjunct treatment of IFN-α in a
patient with complete IFN-γR1 deficiency suffering from
disseminated infection with Mycobacterium avium complex
(MAC) [4]. Although the patient continued to be mycobac-
teremic, hepatosplenomegaly and lymphadenopathy were
reduced which they credited to the additional IFN-α
treatment. In addition, Rapkiewicz et al. describe an IFN-
γR2 deficient child with disseminated MAC who was treated
with antimycobacterials in combination with IFN-α, GM-CSF
or IFN-γ [5]. The authors observed a better defined
granulomatous inflammation and clinical improvement
after he received IFN-α in combination with GM-CSF therapy,
although the contribution of IFN-α to the observed effects of
combined therapy is difficult to establish; this patient
subsequently died during a second episode of IFN-α
treatment [5]. The authors of both reports hypothesized
that the beneficial effects of IFN-α could be attributed to
activation of STAT1 and downstream signalling pathways
shared by IFN-α and IFN-γ [4,5].
In line with our observations, IFN-α was previously found
to negatively regulate IL-12 as well as the resulting IFN-γ
production in mice, in vitro and in vivo [23–25]. For
instance, hypervirulent strains of M. tuberculosis isolates
were shown in mouse models to induce elevated levels of
IFN-α mRNA with a concordant depression in Th1 response
[25]. Additionally, neutralization of IFN-α/β in similar mouse
models led to a significant increase in survival of animals and
a corresponding increase in IL-12p40 mRNA in the lungs [26].
Therefore, in IFN-γR1 deficient patients, inhibition of IL-12
and IL-23 production by IFN-α administration may reduce the
(IFN-γ independent) induced protective effects of these two
cytokines. In mice, IL-23 is needed for the induction of IL-17
producing M. tuberculosis specific T cells in the lung and for
the recall response of these cells after infection with M.
tuberculosis [27]. The Th17 recall response precedes the Th1
recall response, and in the absence of IL-23, both these recall
responses are diminished, resulting in a diminished clearance
of M. tuberculosis from the lungs [27]. These observations
suggest that the inhibition of IL-23 production by IFN-α may
have a negative effect on bacterial clearance.
IFN-α also negated the bactericidal activity of IFN-γ. In
line with these observations, type I interferons are reported
to enhance the intracellular replication of M. bovis in human
monocytes and macrophages [28].Several case reports described the appearance of myco-
bacterial infections in patients receiving IFN-α treatment;
however, also large numbers of patients are treated with
IFN-α apparently without acquiring mycobacterial infections
[29–31]. Administration of aerosolized IFN-α in an uncon-
trolled setting appeared to have a slight beneficial effect in
patients with pulmonary tuberculosis, but randomized
controlled trials have not been done [32]. In five patients
with advanced intractable multidrug-resistant pulmonary
tuberculosis who were treated with IFN-α, no positive effect
was observed [33].
Despite the fact that both IFN-α and IFN-γ cause STAT1
phosphorylation, the effects of these interferons differed
considerably. One explanation for the observed differences
is that phosphorylated STAT1 is incorporated in different
complexes: mainly STAT1 homodimers after IFN-γ stimula-
tion versus mainly STAT1/STAT2/IRF-9 complexes (ISGF3)
after IFN-α stimulation. Both complexes can bind and
activate promoters of interferon-responsive genes: STAT1
homodimers mainly activate promoters that contain gamma
interferon activation site (GAS) elements, while ISGF3
mainly activates promoters that contain interferon-stimu-
lated responsive elements (ISRE). The inhibitory effect of
IFN-α on IFN-γ priming of cells may be explained by the
competition for signalling molecules such as STAT1 when
both stimulations are present at the same time. It would
therefore be interesting to determine the balance between
STAT1/STAT1 homodimers and STAT1/STAT2 after stimula-
tion of cells with either IFN-γ or IFN-α.
Enhanced production of pro-inflammatory cytokines such
as IL-12, IL-23 and TNF and IL-1β in response to IFN-γ is
absent in IFN-γR1 deficient patients, thus leading to low
levels of these cytokines during infection. Pro-inflammatory
cytokines are required to mount an effective protective
immune response against mycobacterial infection [19] and
patients receiving anti-TNF treatment are more susceptible
to mycobacterial infections [34]. Adjunct treatment with
cytokines such as IL-12, IL-23, TNF and IL-1β may have
beneficial effects on the eradication of mycobacterial
infection.
Puzzlingly, monocytes derived from the IFN-γR1 deficient
patient produced higher amounts of IL-12p40 subunit in
response to LPS compared to control derived monocytes. The
reason for this is unclear. It can be hypothesized that due to a
lack of IFN-γ stimulation of the IFN-γR1 deficient monocytes
these cells may have developed a higher LPS-induced
IL-12p40 production, either due to the lack of an as yet
unknown negative feedback of IFN-γ on IL-12p40 production,
or as an active compensation mechanism. However, no
IL-12p70 production by patient-derived cells was observed
and the LPS-induced IL-23 production by patient-derived
monocytes was comparable to that of control cells, suggest-
ing the higher IL-12p40 production does not amount to higher
production of a functional cytokine. The IL-12p40 homo-
dimer that is reportedly produced in mice [35] and that could
potentially be formed by the IL-12p40 molecules has not
been detected in human cells [36].
Taken together, our study did not find support for the
proposed positive effect of IFN-α treatment in mycobacterial
infectionswhile inhibitory effects of IFN-α on pro-inflammatory
cytokine production and inhibition of bactericidal activity may
even be counter-productive. Without evidence backing its
289Effect of IFN-α on IFN-γR1 deficient cellsmerit,we feel one should restrain fromusing IFN-αas additional
treatment in IFN-γR-deficient patients with mycobacterial
infections.
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